July 31, 2013Clinical Pharmacology & Therapeutics

CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Patients

View Full Paper

Ask AI

Bookmark

Why the study?

Does CD34(+) stem cell therapy improve clinical outcomes in patients with nonischemic dilated cardiomyopathy?

Population

Patients with nonischemic dilated cardiomyopathy

Design

Review

Authors

BVBojan VrtovecLjubljana University Medical Centre GPGregor PoglajenHeart Failure & Transplant MSMehmet Şükrü SeverBayburt University

Discussion

Member takes

Implication

Leaves open whether CD34+ therapy improves outcomes in nonischemic dilated cardiomyopathy; warrants prospective RCTs on clinical endpoints.

Structured PICO

Does CD34(+) stem cell therapy improve clinical outcomes in patients with nonischemic dilated cardiomyopathy?

Population

Patients with nonischemic dilated cardiomyopathy

Intervention

CD34(+) stem cell therapy

Outcome

Long-term clinical effects and potential underlying mechanisms

CD34+ stem cell therapy may offer a neoangiogenic treatment modality for patients with nonischemic dilated cardiomyopathy by contributing to the formation of new blood vessels.

Cite This Study

Vrtovec et al. (2013) studied this question.

synapsesocial.com/papers/6a95215095cf49f4209e702d https://doi.org/10.1038/clpt.2013.134

View Full Paper

Ask AI

Bookmark

Implication

Leaves open whether CD34+ therapy improves outcomes in nonischemic dilated cardiomyopathy; warrants prospective RCTs on clinical endpoints.

CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Patients

Discussion

Member takes

Implication

Structured PICO

Cite This Study

CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Patients

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider